Until recently, the term “symbolic” bore negative connotations in AI because it harkened back to the failures to achieve symbolic thinking during the so-called “AI winter” of the 1980s. Since then, generative AI has demonstrated the masterly capacities of neural networks at scale.
Generative AI has relieved doctors of their administrative and cognitive burdens, for example, by handling administration and paperwork, including clinical summaries. More than 70 percent of healthcare organizations
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
RSNA: GE HealthCare Unveils Aurora SPECT/CT: A New Era in Precision Imaging
What You Should Know:
- GE HealthCare has announced the launch of Aurora, a revolutionary dual-head SPECT/CT system designed to enhance diagnostic capabilities and improve patient care.
- Unveiled at the Radiological Society of North America (RSNA) 2024 Annual Meeting, Aurora offers advanced features and AI-powered solutions to support precision medicine and personalized care.
Advancing SPECT/CT Imaging
Aurora combines functional imaging from SPECT with anatomical details from
Read More
Unlocking Real-World Data to Advance Precision Medicine in 2025
The healthcare industry is a wellspring of data, from electronic health records to data from wearables, health insurance claims, and a multitude of real-world data (RWD) points. While RWD has been utilized to improve drug discovery and clinical services, recent technological advances in data management, artificial intelligence, and bioinformatics are beginning to reveal its transformative potential in healthcare, especially within precision medicine. As the industry seeks to employ new
Read More
Aignostics Secures $34M to Advance AI-Powered Pathology and Precision Medicine
What You Should Know:
- Aignostics, a leading AI company specializing in pathology data analysis, raised $34M in Series B funding, led by ATHOS with participation from Mayo Clinic and growth financing from HTGF, alongisde existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and VC Fonds Technologie managed by IBB Ventures.
- Aignostics combines proprietary access to multimodal clinical data with cutting-edge AI technology and rigorous
Read More
CancerIQ Raises Growth Capital for Personalized Cancer Detection
What You Should Know:
- CancerIQ, a Chicago, IL-based precision health platform focused on empowering healthcare providers to personalize cancer prevention and early detection announced it has secured a growth funding package from Decathlon Capital Partners.
- While specific financial details of the transaction were not disclosed, the investment will enable CancerIQ to further develop its digital tools, introduce new offerings, and strengthen partnerships with healthcare
Read More
Caresyntax Secures $180M to Advance Precision Surgery Platform
What You Should Know:
- Caresyntax, a leader in vendor-neutral precision surgery platforms raises $180M in funding, comprised of $80M in equity and up to $100M in growth debt, will fuel the company's continued growth and development of its AI-powered surgical platform.
- The funding round was led by a consortium of prominent investors, including Symbiotic Capital, MTIP AG, BIONIQ Capital, and BlackRock Innovation Capital. This significant investment demonstrates the growing
Read More
Mindera Health Secures $14M to Advance Commercialization of Psoriasis Precision Medicine Test
What You Should Know:
- Mindera Health, a leading developer of precision medicine solutions for dermatology, raises $14M convertible note financing led by Mountain Group Partners.
- The funding will accelerate the commercialization of Mindera’s flagship product, Mind.Px™, a groundbreaking test that predicts patient response to psoriasis treatments.
Revolutionizing Psoriasis Treatment
Mind.Px™ is a proprietary biomarker test that analyzes a patient’s skin sample to determine the
Read More
Why Precision Medicine Demands a Completely New Type of Database
Precision medicine is revolutionizing healthcare - by optimizing the efficiency and therapeutic benefit for particular groups of patients, especially by using genetic or molecular profiling. This approach enables a range of health disciplines, including disease prediction, prevention and the resulting treatments, diagnostic screening for prenatal and newborns, and screening for rare diseases and cancer types. For life sciences, the ability to peer into high-resolution molecular profiles has
Read More
Proscia and Nucleai Partner to Integrate Predictive Biomarker Solutions
What You Should Know:
- Proscia, a leader in artificial intelligence (AI)-powered pathology solutions, and Nucleai, a leading spatial AI biomarker company, announced a strategic partnership today. This collaboration aims to revolutionize precision medicine by integrating Nucleai's advanced biomarker technology with Proscia's Concentriq® software platform.
- By harnessing the power of AI and digital pathology, this partnership offers the potential to fundamentally improve the
Read More
Foresite Capital Closes $900M Fund Targeting Precision Medicine & Innovation
What You Should Know:
- Foresite Capital, a San Francisco, CA-based healthcare and life sciences investment firm, announced today the successful closing of its sixth fund with a significant $900M in capital commitments. This new fund fuels Foresite's mission to invest in groundbreaking technologies across the healthcare spectrum.
- Fund VI attracted a diverse group of limited partners, including university endowments, charitable foundations, medical institutions, pension funds,
Read More
